Using cell cycle analysis, we confirmed that this antibody had no effect on the survival of these cancer cells, since VEGFR1 is mostly expressed internally and not on the surface of breast cancer cells as expected (unpublished data). The gene discussed is FLT1; the disease is breast carcinoma.